Biaffin

Newsletter

kinases protein kinase inhibitors signaling activators kinase substrates antibodies bioluminescence assays
Recombinant human KLK-6 Protein, His Tag, 5x200µg  

Recombinant human KLK-6 Protein, His Tag, 5x200µg

Recombinant human KLK6 (rhKLK6) Glu17-Lys244 was produced in human HEK293 cells, His Tag

Synonym
recombinant human protein, KLK6, KLK-6, Kallikrein-6, Kallikrein6, Kallikrein

More details

KL6-H5222-1K

Availability: within 7 days

1 440,00 €

Background
Kallikreins are a subgroup of serine proteases, enzymes capable of cleaving peptide bonds in proteins. In humans, tissue kallikrein-related peptidases (KLKs) encode a family of fifteen closely related serine proteases. Kallikreins are responsible for the co-ordination of various physiological functions including blood pressure, semen liquefaction and skin desquamation. Serine protease which exhibits a preference for Arg over Lys in the substrate P1 position and for Ser or Pro in the P2 position. Shows activity against amyloid precursor protein, myelin basic protein, gelatin, casein and extracellular matrix proteins such as fibronectin, laminin, vitronectin and collagen. 
Kallikrein-6 (KLK6) also known as Bssp, Klk7, MGC9355, PRSS18, PRSS9, SP59 and hK6. KLK6 is one of the fifteen kallikrein subfamily members, and is regulated by steroid hormones. In tissue culture, KLK6 has been found to generate amyloidogenic fragments from the amyloid precursor protein, suggesting a potential for involvement in Alzheimer\'s disease. The prior studies indicate KLK6 is elevated at sites of central nervous system (CNS) inflammation and which shows regulated expression with T cell activation. Notably, KLK6 is also elevated in the serum of multiple sclerosis (MS) patients. KLK6 promotes lymphocyte survival by a mechanism that depends in part on activation of PAR1. KLK6 are also associated with neuronal plasticity in the central nervous system.[1-4]

Source
Recombinant human KLK6 protein (rhKLK6) Glu17-Lys244 (Accession # (AAH15525) fused with a 6x his tag at the C-terminus was produced in human HEK293 cells.

Molecular Characterization
rhKLK6, fused with 6×his tag at the C-terminal and has a calculated MW of 18 kDa (mature form) or 26 kDa (pro form) expressed. The predicted N-terminal is Glu17 or Ser 81. Protein migrates as 23 kDa or 33 kDa in reduced SDS-PAGE resulting from autolysis and glycosylation.

Endotoxin
Less than 1.0 EU per 1 μg by the LAL method.

Purity
>95% as determined by SDS-PAGE. All lots are greater than 95% pure.

Formulation
Bulk protein in a 0.22 μm filtered solution of PBS, pH 7.4 and delivered as liquid formulation or lyophilized powder.Normally 5-8% trehalose and mannitol are added as protectants before lyophilization.

Reconstitution
See Certificate of Analysis for details of reconstitution instruction and specific concentration.

Storage
Avoid repeated freeze-thaw cycles. No activity loss was observed after storage at:
In lyophilized state for 1 year (4°C-8°C); After reconstitution under sterile conditions for 1 month (4°C-8°C) or 3 months (-20°C to -70°C).

References

(1) Tamura H, et al., 2006, J Physiol 1;570 (3): 541–51.
(2) Scarisbrick IA, et al., 2001, PLoS One., 28;6(3):e18376.
(3) Ashby EL., et al., 2010, Brain Res, 1363:1-10.
(4) Kim JT, et al., 2011, Cancer., 117(12):2608-19.